Yamazawa (9993) · FactRestated
Growth in Sales of Infection-Related Products
First written in FY2023-Q2. 2 of 3 entries say "Restated". Latest entry: FY2023.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
Fluctuations in Demand for Infection Control Products Due to Infectious Disease Outbreaks and Changes in Preventive AwarenessA theme 19 companies write about · 6 as a headwind · 12 as a tailwind
The whole theme swung hardest in 2023: 3 of 13 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「Sales of antigen test kits, cold remedies, antipyretic analgesics, masks and other products increased as the novel coronavirus infection spread.」
The company continues to report growth in sales of antigen test kits, cold remedies, antipyretic analgesics, masks and other products amid the spread of infectious diseases. - FY2023-Q3RestatedAnnual report
「Sales of antigen test kits, cold remedies, antipyretic analgesics, masks and other products increased as the novel coronavirus infection spread.」
The company continues to report growth in sales of antigen test kits, cold remedies, antipyretic analgesics, masks and other products amid the spread of the novel coronavirus infection. - FY2023-Q2First statedAnnual report
「Sales of antigen test kits, cold remedies, antipyretic analgesics, masks and other products increased as the novel coronavirus infection spread.」
The company newly reported that sales of antigen test kits, cold remedies, antipyretic analgesics, masks and other products increased amid the spread of the novel coronavirus infection.